WO2001037861A1 - A conjugate of a collagen ii-binding fragment and an arthritis-affecting pharmaceutical substance - Google Patents
A conjugate of a collagen ii-binding fragment and an arthritis-affecting pharmaceutical substance Download PDFInfo
- Publication number
- WO2001037861A1 WO2001037861A1 PCT/SE2000/002293 SE0002293W WO0137861A1 WO 2001037861 A1 WO2001037861 A1 WO 2001037861A1 SE 0002293 W SE0002293 W SE 0002293W WO 0137861 A1 WO0137861 A1 WO 0137861A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- chondroadherin
- collagen
- arthritis
- conjugate
- conjugate according
- Prior art date
Links
- 102000008186 Collagen Human genes 0.000 title claims abstract description 84
- 108010035532 Collagen Proteins 0.000 title claims abstract description 84
- 229920001436 collagen Polymers 0.000 title claims abstract description 84
- 206010003246 arthritis Diseases 0.000 title claims abstract description 23
- 239000003814 drug Substances 0.000 title claims abstract description 15
- 239000012634 fragment Substances 0.000 title claims abstract description 12
- 102100032925 Chondroadherin Human genes 0.000 claims abstract description 95
- 108010059427 chondroadherin Proteins 0.000 claims abstract description 95
- 102000004127 Cytokines Human genes 0.000 claims abstract description 15
- 108090000695 Cytokines Proteins 0.000 claims abstract description 15
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims abstract description 11
- 239000000126 substance Substances 0.000 claims abstract description 8
- 208000024891 symptom Diseases 0.000 claims abstract description 7
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 6
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 6
- 238000010382 chemical cross-linking Methods 0.000 claims abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- 230000002917 arthritic effect Effects 0.000 claims description 6
- 102000005741 Metalloproteases Human genes 0.000 claims description 5
- 108010006035 Metalloproteases Proteins 0.000 claims description 5
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 claims description 5
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 claims description 4
- 102100024289 Metalloproteinase inhibitor 4 Human genes 0.000 claims description 3
- 108050006579 Metalloproteinase inhibitor 4 Proteins 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 108010093564 inter-alpha-inhibitor Proteins 0.000 claims description 3
- 150000007523 nucleic acids Chemical group 0.000 claims description 3
- 239000002753 trypsin inhibitor Substances 0.000 claims description 3
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 claims description 2
- 102100026261 Metalloproteinase inhibitor 3 Human genes 0.000 claims description 2
- 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 claims description 2
- 108010031429 Tissue Inhibitor of Metalloproteinase-3 Proteins 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- 239000003541 chymotrypsin inhibitor Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 108010044091 Globulins Proteins 0.000 claims 1
- 102000006395 Globulins Human genes 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 30
- 102000004169 proteins and genes Human genes 0.000 abstract description 28
- 210000000845 cartilage Anatomy 0.000 abstract description 24
- 210000001519 tissue Anatomy 0.000 abstract description 20
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 abstract description 6
- 210000002744 extracellular matrix Anatomy 0.000 abstract description 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 5
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 abstract description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 abstract description 4
- 239000000430 cytokine receptor antagonist Substances 0.000 abstract description 4
- 238000010353 genetic engineering Methods 0.000 abstract description 2
- 230000001717 pathogenic effect Effects 0.000 abstract description 2
- 102000000503 Collagen Type II Human genes 0.000 description 27
- 108010041390 Collagen Type II Proteins 0.000 description 27
- 235000018102 proteins Nutrition 0.000 description 27
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 26
- 230000003993 interaction Effects 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 19
- 108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 description 16
- 239000000562 conjugate Substances 0.000 description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 239000011780 sodium chloride Substances 0.000 description 13
- 210000004899 c-terminal region Anatomy 0.000 description 12
- 239000011159 matrix material Substances 0.000 description 12
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 11
- 238000001493 electron microscopy Methods 0.000 description 11
- 238000005119 centrifugation Methods 0.000 description 10
- 102000035195 Peptidases Human genes 0.000 description 9
- 108091005804 Peptidases Proteins 0.000 description 9
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 9
- 101000942744 Homo sapiens Chondroadherin Proteins 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 102000004237 Decorin Human genes 0.000 description 6
- 108090000738 Decorin Proteins 0.000 description 6
- 102000017177 Fibromodulin Human genes 0.000 description 6
- 108010013996 Fibromodulin Proteins 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 6
- 239000000470 constituent Substances 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 210000004901 leucine-rich repeat Anatomy 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 5
- 101000942754 Bos taurus Chondroadherin Proteins 0.000 description 5
- 239000004365 Protease Substances 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 210000001188 articular cartilage Anatomy 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 108010044426 integrins Proteins 0.000 description 5
- 102000006495 integrins Human genes 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000007975 buffered saline Substances 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229920000136 polysorbate Polymers 0.000 description 4
- 235000019833 protease Nutrition 0.000 description 4
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 4
- 102000004954 Biglycan Human genes 0.000 description 3
- 108090001138 Biglycan Proteins 0.000 description 3
- 101710176668 Cartilage oligomeric matrix protein Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 102000011681 Lumican Human genes 0.000 description 3
- 108010076371 Lumican Proteins 0.000 description 3
- 108010072582 Matrilin Proteins Proteins 0.000 description 3
- 102000055008 Matrilin Proteins Human genes 0.000 description 3
- 235000013290 Sagittaria latifolia Nutrition 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 210000001612 chondrocyte Anatomy 0.000 description 3
- 235000015246 common arrowhead Nutrition 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000004255 ion exchange chromatography Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 230000007306 turnover Effects 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 102100027473 Cartilage oligomeric matrix protein Human genes 0.000 description 2
- 102000004427 Collagen Type IX Human genes 0.000 description 2
- 108010042106 Collagen Type IX Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 108060003393 Granulin Proteins 0.000 description 2
- -1 II- 1 Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 241000219061 Rheum Species 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 102000018594 Tumour necrosis factor Human genes 0.000 description 2
- 108050007852 Tumour necrosis factor Proteins 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 102000013373 fibrillar collagen Human genes 0.000 description 2
- 108060002894 fibrillar collagen Proteins 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- NCQJBPXXRXOIJD-UHFFFAOYSA-N 3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-naphthalen-2-ylpropanoic acid Chemical compound C1=CC=CC2=CC(C(CC(O)=O)NC(=O)OC(C)(C)C)=CC=C21 NCQJBPXXRXOIJD-UHFFFAOYSA-N 0.000 description 1
- ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000055007 Cartilage Oligomeric Matrix Human genes 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010017642 Integrin alpha2beta1 Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 101710141795 Ribonuclease inhibitor Proteins 0.000 description 1
- 229940122208 Ribonuclease inhibitor Drugs 0.000 description 1
- 102100037968 Ribonuclease inhibitor Human genes 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 230000002788 anti-peptide Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000022159 cartilage development Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000003349 osteoarthritic effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- SFIHWLKHBCDNCE-UHFFFAOYSA-N uranyl formate Chemical compound OC=O.OC=O.O=[U]=O SFIHWLKHBCDNCE-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- the present invention relates to a novel conjugate consisting of a collagen-binding fragment of chondroadherin covalently linked to a pharmaceutically interesting substance such as cytokines, cytokine-inhibiting substances and protease inhibitors.
- the invention also relates to pharmaceutical compositions containing the new conjugates.
- the major constituents of the extracellular matrix of cartilage are type II collagen, proteoglycans and a number of proteins including some of the minor collagens.
- the matrix macromolecules have very different structural and functional characteristics and each component contributes differently to the organisation and properties of the tissue.
- the matrix are assembled in multicomponent networks where the interactions between the matrix constituents are essential for the maintenance of tissue integrity (Heinegard et al., editors. Osteoarthritis. 1 ed. Oxford University Press; 1998; 7.2.1, Biochemistry and metabolism of normal and osteoarthritic cartilage, p. 74 - 84).
- chondroadherin One of the non-collagenous proteins in cartilage is chondroadherin. It was first isolated from bovine tracheal cartilage (Larsson et al., J. Biol. Chem. 1991; 266:20428-33). The protein and cDNA sequence of bovine chondroadherin (Neame et al., J. Biol. Chem. 1994;269:21547-54) showed that it belongs to the family of leucine-rich repeat (LRR) proteins (Patthy, J. Mol. Biol. 1987; 198:567-77).
- LRR leucine-rich repeat
- LRR proteins have several members in extracellular matrices and are characterised by a conserved sequence xLxxLxLxx(N,C,T)x(L,I) followed by 9 to 14 less conserved residues. This sequence may be repeated up to 30 times, while in the extracellular proteins it usually occurs 10 to 11 times and in other subgroups 5 - 6 times.
- the repeat domain is flanked by two cysteine-bonded loops and usually short extensions in the N-terminal and C-terminal regions of the protein.
- the crystal structure of one member of the LRR protein family, ribonuclease inhibitor has been solved and refined at 2.5 A (Kobe et al., Nature 1993; 366:751-6).
- each LRR is composed of a ⁇ -sheet and an ⁇ -helix.
- the ⁇ -sheet that forms the consensus part of the LRR and the less conserved helices are exposed at different faces of the protein.
- the repeats are larger and higher in number than in the matrix proteins, it is likely that at least some features are represented in other members of this family.
- a common property of the LRR proteins is that their 3- dimensional structure seems to facilitate protein-protein interactions. In chondroadherin the LRR sequence is repeated 11 times. This protein differs from other members of this ECM family by having two cysteine-bonded loops in the C- terminal region and also by lacking any N-terminal extensions.
- chondroadherin The precise function of chondroadherin is unknown. It has been shown to bind cells via the ⁇ 2 ⁇ integrin, without stimulating cell spreading (Camper et al., J. Cell. Biol. 1997, 138, 1159-67).
- the collagen family of proteins includes several members which are restricted to cartilage extracellular matrix. The collagens can be classified on the basis of their molecular shape and properties. Collagen type II is the major collagen found in cartilage. It is a fibril -forming collagen, composed of three identical polypeptide chains.
- the helix has surface characteristics promoting interactions with other matrix constituents.
- collagen associate to form fibrils which in turn are linked in interactions via cross- bridging molecules.
- These include other collagens such as collagen type IX (Eyre et al., FEBS Lett. 1987, 220: 337-41), as well as non-collagenous molecules such as decorin, fibromodulin (Hedbom et al., J. Biol. Chem. 1993, 268: 27307-12), lumican (Rada et al., Exp. Eye. Res. 1993, 56: 635-48), the latter also being members of the LRR family of proteins.
- cartilage oligomeric matrix protein COMP
- cytokines mediates and induces inflammatory reactions. They are also key components of the immune system.
- the change of cartilage matrix turnover in arthritic diseases is thought to be driven by cytokines. They induce production of proteases and activates them via unknown mechanisms. It would therefore be possible to therapeutically treat and/or alleviate the symptoms of arthritic diseases by administrating a therapeutically effective amount of cytokine antagonists and/or protease inhibitors in order to counteract the change of cartilage matrix turnover.
- a major problem relating to therapeutic use of these compounds is to provide a suitable way of administrating them, so that they can reach their target, e.g. an arthritis-affected joint, in a sufficiently efficient way.
- the above mentioned problem can be overcome by providing a conjugate of a collagen II-binding chondroadherin fragment and an arthritis-affecting pharmaceutical substance, such as a cytokine, a cytokine antagonist and/or a protease inhibitor. It has turned out that chondroadherin specifically interacts with collagen II thereby forming a complex. Release of cartilage extracellular matrix components, such as chondroadherin and collagen II is a symptom of arthitis.
- the inventive conjugate can be manufactured by chemical crosslinking.
- the arthitis-affecting pharmaceutical substance is a protein or a peptide
- the conjugate can be a fusion protein and be produced by genetic engineering techniques.
- the term "arthritis-affecting pharmaceutical substance” can be a cytokine, a cytokine antagonist and/or a protease inhibitor.
- cytokines are interleukins, such as II- 1, tumour necrosis factor alfa (TNF ⁇ ), ⁇ jAT, PR3, and MPO.
- the arthritis-affecting substance is a protease inhibitor capable of inhibiting metalloproteases that might occur in cartillage tissue.
- protease inhibitors are oti -antitrypsin, cti -antichymotrypsin, inter- ⁇ -trypsin inhibitor, ⁇ 2 macroglobulin and tissue inhibitors of metalloproteinases (TIMP-1 to TIMP-4).
- Fig. 1 discloses SDS-PAGE of collagen II and recombinant chondroadherin that are used in the surface plasmon resonance assay. Figures indicate that the main part of collagen type II and chondroadherin used are monomers;
- Fig. 2 describes zonal rate sedimentation of chondroadherin containing complexes on glycerol gradients.
- the upper panel shows SDS-PAGE and Coomassie-staining of fractions from gradient centrifugation in glycerol of flow through from ion exchange chromatography of medium from APMA-treated bovine cartilage. Bottom fractions are to the left and top fractions to the right. Collagen type II is mainly present in the upper fractions.
- the lower panel shows Western blot analysis of chomdroadherin in the same fractions as above. Chondroadherin is mainly present in the upper fractions;
- Fig. 3 relates to electron microscopy of collagen II - chondroadherin complexes.
- Fig. 3 A shows electron microscopy of collagen type II - chondroadherin complexes in flow through from ion exchange chromatography of medium from APMA-treated bovine cartilage. Complexes are indicated by arrows.
- the polarity of collagen is defined by antibody F4, indicated by arrow head.
- Fig. 3B shows the same thing as fig. 3 A but with addition of gold-labeled affinity-purified antibodies raised against bovine chondroadherin showing that the protein interacting with collagen type II is chondroadherin.
- Complexes are indicated by an arrow.
- the polarity of collagen is defined by antibody F4, indicated by an arrow head.
- Fig. 3C describes electron microscopy of reconstituted complexes of recombinant chondroadherin and collagen type II. Complexes are indicated by an arrow.
- the polarity of collagen is
- Fig. 4 relates to distribution of bound chondroadherin along monomeric collagen II.
- the upper panel (A) shows the distribution of chondroadherin along collagen type II observed in the complexes isolated from cartilage.
- the relative frequency denotes the fraction of chondroadherin molecules which are bound to a given site on collagen II.
- the C-terminus is at 0 nm as determined by using an antibody against the C-terminal end of collagen type II.
- the lower panel (B) shows the binding sites of the in vitro reconstituted collagen II - chondroadherin complexes;
- Fig. 5 shows characteristics of the chondroadherin - collagen II interaction.
- Surface plasmon resonance assay (BIAcore) showing interaction of collagen type II and chondroadherin. The figures show the association phase (0 - 60 seconds) and the dissociation phase (0 - 60 seconds).
- Panel A shows interaction of collagen type II on immobilised chondroadherin.
- Panel B shows interaction of chondroadherin on immobilised collagen type II;
- Fig. 6 discloses the cDNA sequence for human chondroadherin and its deduced amino acid sequence. The signal sequence is indicated by bolded letters. Stop codons are indicated by dots.
- cartilage matrix turnover in arthritic diseases is thought to be driven by cytokines. Among all, they induce production of proteinases. These en2ymes degrade matrix constituents, thereby affecting tissue integrity.
- cytokines cytokines
- en2ymes degrade matrix constituents, thereby affecting tissue integrity.
- cartilage components particularly chondroadherin
- APMA matrix metalloproteinases
- Chondroadherin was among the molecules released to the medium in buffers that show little extraction on their own. Zonal rate centrifugation of the release material in glycerol gradients shows that collagen and chondroadherin cofractionates.
- the K D of the interaction was calculated, both for the interaction when chondroadherin was immobilised and when collagen was immobilised.
- the K D in the nanomolar range, differs somewhat depending on which component in the interaction pair that was immobilised.
- the tighter binding of collagen to immobilised chondroadherin may result from the two binding sites for chondroadherin on collagen enhancing the binding strength as compared to chondroadherin interacting with immobilised collagen.
- This assumption is further strengthened by the difference in K D :s using models allowing for 1 and 2 binding sites on the analyte, respectively. It is also possible that microenvironment on the chip becomes somewhat dependent on which ligand was immobilised.
- the complexes released from the cartilage and characterised by electron microscopy consist of collagen type II with one or two chondroadherin molecules attached. Neither collagen nor chondroadherin seem to be degraded indicating that their release is dependent on cleavage of their anchorage in the tissue.
- the complexes consist of intact chondroadherin and intact collagen, which further strengthen the assumption that these complexes occur in vivo.
- the collagen in the complexes is monomeric but in a mature form without peptides. This is particularly interesting in view of the very low abundance of non-aggregated collagen molecules being highly interactive. Since collagen was not in its proform, it appears to have been processed in the tissue. Whether this was a result of the induced proteolysis is not clear. However, all collagen was processed, at the same time as fragmentation of other proteins like chondroadherin and COMP was limited, indicating that processing had occurred prior to APMA treatment.
- chondroadherin In articular cartilage chondroadherin is located territorially, while most other LRR proteins also known to interact with collagen such as decorin and fibromodulin are located interterritorially, where they have structural functions in the network. It is reasonable to speculate that proteins located more close to the cells have a regulatory role, communicating between cells and matrix. Both collagen type II and chondroadherin have been shown to bind chondrocytes (Sommarin et al., Exp. Cell Res. 1989, 184: 181-92). These cells are known to express several different integrins on their surface, including the ⁇ i ⁇ i and ⁇ 2 ⁇ integrins (Durr et al., Exp. Cell Res.
- the ⁇ 2 ⁇ 1 integrin has been shown to be a receptor for chondroadherin (Camper et al., J. Cell. Biol. 1997, 138: 1159-67) whereas both these integrins have been shown to bind collagen type II. Even though they in part interact with the same integrin only collagen is able to induce spreading of the cells when grown on collagen and chondroadherin, respectively (Sommarin et al., Exp. Cell Res. 1989, 184: 181-92).
- a complex system is created. This potentially includes crossbridging of a number of receptors. Future work should sort out the consequences of interactions of individual components in comparison to that of the complexes, e.g. with regard to ensuing intracellular signalling and cell function.
- this interaction between chondroadherin and collagen II can be utilised for medical purposes, such as for treating and/or alleviating the symptoms of arthritic diseases such as rheumatism and rhematoid arthritis.
- a symptom of such diseases is that both chondroadherin and collagen II are released in the synovial fluid and in serum in connection with degradation of matrix constituents.
- cytokines are believed to cause this degradation by inducing production of proteinases.
- the present invention provides conjugates comprising a) a chondroadherin fragment having the ability to specifically bind to collagen II, and b) and an arthritis-affecting pharmaceutical substance, such as a cytokine, a cytokine antagonist and/or a protease inhibitor.
- an arthritis-affecting pharmaceutical substance such as a cytokine, a cytokine antagonist and/or a protease inhibitor.
- suitable cytokines are interleukins, such as II- 1, tumour necrosis factor alfa (TNF ⁇ ), ⁇ i AT, PR3, and MPO.
- tissue inhibitors of metalloproteinases are particularly preferred as an arthritis-affecting pharmaceutical substance.
- Other protease inhibitors such as ⁇ i-antitrypsin, ⁇ antichymotropsin, inter- ⁇ -tryp sin inhibitor, ⁇ 2 - macroglobulin and anti-trombin III could also be used as an arthritis-affecting pharamaceutical substance.
- a conjugate according to the present invention comprising chondroadhein connected to a protease, such as TIMP-1, TIMP-2, TIMP-3 or TIMP-4 could be used to protect cartillage tissue from proteolytic degradation.
- the chondroasherin part of the conjugate binds to collagen II, and accordingly the conjugate will be located in the cartillage tissue.
- the protease part is therefor capable of inhibiting proteases directly in the cartillage tissue.
- the conjugate according to the present invention can be manufactured by chemically cross-linking a) chondroadherin or a collagen II-binding fragment thereof, and b) the arthritis-affecting pharmaceutical substance. This can for instance be carried out by reactions involving common and well-known chemical crosslinkers, such as glutaraldehyde.
- the conjugates of the present invention can of course also be produced using recombinant DNA techniques.
- Nucleic acid sequences encoding a) chondroadherin or a collagen II-binding fragment thereof, and b) the arthritis-affecting pharmaceutical substance are ligated together in order to obtain a fused nucleic acid encoding a fusion protein comprising a functionally efficient a) chondroadherin or a collagen II-binding fragment thereof, and b) a functionally efficient arthritis- affecting pharmaceutical substance.
- Suitable techniques that can be used for obtaining such a fusion protein can be found in Sambrook: Molecular Cloning, A Laboratory Manual. Second Edition.
- the chondroadherin part of the conjugate according to the present invention can be the complete condroadherin as disclosed in Fig. 6, or alternatively it can be a truncated derivative comprising at least 10 amino acids. However, such a truncated chondroadherin derivative must be able to specifically bind to collagen type II.
- the present invention also provides pharmaceutical compositions comprising the conjugate according to the invention together with a pharmaceutically acceptable carrier.
- the pharmaceutical composition of the invention is intended for parenteral administration, preferably directly into a tissue affected with an arthritic disease, such as an affected joint.
- the composition contains a therapeutically effective amount of conjugate in sterile physiological saline.
- Bayliss was screened using a 450 bp bovine chondroadherin cDNA probe. A 1444 bp clone was isolated and purified with Plasmid Midi Kit (Qiagen). DNA sequencing was performed in full on both strands by standard double-strand dideoxy termination sequencing using T3, T7 and synthetic internal specific primers.
- a polyclonal antiserum against human chondroadherin was raised by immunising a rabbit with a peptide from the C-terminal region of the protein (GQHIRDTDAFRS,
- This vector is maintained extrachromosomally in eucaryotic cells and expresses high levels of recombinant protein (Young et al., Gene 1988, 62, 171 - 85).
- the transcription is driven by the cytomegalovirus promoter included in the pCEP4 vector.
- the endogenous signal peptide of human chondroadherin was used.
- the construct in pCE04 was transfected to human EBNA cells by using lipofectamine (Gibco, BRL). After transfection the cells were grown in Dulbecco's modified Eagle's medium (DMEM)(Gibco, BRL) containing 10 % fetal calf serum.
- DMEM Dulbecco's modified Eagle's medium
- hygromycin (Calbiochem)(160 ⁇ g/ml) was added to the culture medium as a selector.
- the cells were expanded and when left confluent the media were changed to DMEM without fetal calf serum.
- the cells were left for 48 hours after which the medium was harvested and centrifuged for 5 minutes at 3000xg.
- Phenyl methyl sulfonylfluoride (1 mM, final concentration) was added as a protease inhibitor.
- One liter of collected medium was diluted 4 times to a final concentration of 20 mM Tris, pH 7.3 and applied to a CM52 column previously equilibrated in 20 mM Tris, pH 7. The column was washed with 20 mM Tris and eluted with a gradient of from 0 to 0.5 M NaCl in 20 mM Tris, pH 7.
- the purity and identity of the protein was confirmed by SDS-PAGE and Western blotting using antibodies raised against the C-terminal region of human chondroadherin.
- Proteinases activated by APMA were inhibited by adding EDTA to a final concentration of 9.8 mM. The supernatant was finally made particle-free by centrifugation in a Beckman Ti50.2 rotor at 43000 rpm (100,000 xg) for one hour at 4 °C.
- Collagen II was purified from pepsin-digested bovine articular cartilage as previously described (Miller, Biochemistry 1972, 11, 4903-9; Vogel et al., Biochem. J. 1984, 223, 587-97). The purity of collagen II was confirmed by SDS- PAGE (fig. 1).
- DE52 column ( ⁇ 10 ⁇ g/ml) were prepared for electron microscopy either directly or after incubation with gold-labeled affinity-purified antiserum against bovine chondroadherin.
- Recombinant chondroadherin and collagen type II were preincubated and treated in the same manner as samples isolated from tissue extract.
- Samples were adsorbed to 400 mesh carbon-coated copper grid which was previously rendered hydrophilic by glow-discharge at low pressure in air. The grid was immediately blotted, washed with two drops of water and stained with 0.75 % uranyl formate for 15 seconds.
- antibodies were labeled with colloidal gold of 3 nm size as previously described (Baschong et al., J. Electron. Microsc. Tech. 1990, 14:313-23).
- Chondroadherin (35 ⁇ l at 100 ⁇ g/ml) was immobilised at 25 °C at a flow rate of 5 ⁇ l/min.
- One surface was used as negative control and contained no coupled protein. Remaining activated groups were blocked with 40 ⁇ l of 1M ethanolamine, pH 8.5.
- the binding assay was performed at 25 °C by using pepsinised collagen II at different concentations ranging from 0.09 to 6 ⁇ g/ml in 10 mM Hepes, 0.15 M NaCl, 0.05% Tween, pH 7.4 applied at 40 ⁇ l/min.
- the surface was regenerated by using 0.5 M acetic acid, 2 M NaCl followed by 0.1 M NaHC0 3 , 2 M NaCl, pH 9.2.
- pepsinised collagen type II (2.1 mg/ml in 0.1 M acetic acid) was diluted to 100 ⁇ g/ml in 10 mM sodium citrate, pH 3.2 and immediately immobilised under the same conditions as above (running buffer: 10 mM Hepes, 0.15 M NaCl, 0.05% tween, pH 7.4).
- the immobilisation of collagen type II resulted in 3000 RU.
- the binding assay was performed at 25 °C by using recombinant chondroadherin at different concentrations ranging from 0.03 to 4 ⁇ g/ml in lOmM Hepes, 0.15 M NaCl, 0.05% Tween, pH 7.4 applied at 40 ⁇ l/ml.
- the surface was regenerated by using 10 mM Hepes, 2M NaCl, pH 7.4 followed by 0.1 M NaHC0 3 , 2 M NaCl, pH 9.2. lo
- the BIAevaluation software (version 3.0) was used to calculate the different binding constants (K D )(Fagerstam et al., J. Chromatogr. 1992, 597:397-410).
- Genomics 1997, 45:379-85 certain differences were found. At position 114 in the sequence leucine was found instead of valine, and at position 166 alanine was found instead of proline. Our sequence at these positions was found to be in agreement with the sequences from mouse (Landgren et al., Genomics 1998, 47: 84- 91), rat (Shen et al., Biochem. J. 1998, 330:549-57), and cow (Neame et al., J. Biol.
- the recombinant chondroadherin was eluted from the CM52 column at an ionic strength of 0.18 - 0.22 M NaCl.
- the yield of native recombinant chondroadherin was between 1 and 2 ⁇ g/ml culture medium.
- the protein appears pure as shown by SDS-PAGE (fig. 1) and wastern blotting using antibodies raised against the C- terminal region of the protein.
- Chondroadherin exists in two forms that differ by nine amino acids in the C-terminal. Both forms are expressed by EBNA cells and upon purification on a CM52 ion exchanger they elute differently, in partly overlapping fractions.
- the chondroadherin pool then separated into two fractions, one passing through and one being retained on the column.
- the latter was eluted together with several proteins, including biglycan as a major component, at a sodium acetate concentration of 0.7 - 0.8 M.
- the pool passing through the DE column contained collagen II ⁇ l -chains (as deduced from migration on SDS-PAGE under non-reduced and reduced conditions) as well as chondroadherin (as detected by Western blot) and a few other components. Among those other components as a prominent band was identified as the C-terminal propeptide of collagen II by western blot (data not shown).
- the pool containing collagen and chondroadherin, as well as other components was further fractionated by zonal rate centrifugation and analysed by electron microscopy.
- Samples of the flow through from the DE52 column, containing several different molecular entities was further fractionated by zonal centrifugation in glycerol gradients.
- the composition of the various fractions was studied by SDS-PAGE electrophoresis and Western blotting of non-reduced samples. Collagen type II was detected in the upper part of the gradient with the slowest sedimentation (fig. 2).
- the same fractions from an identical gradient also contained chondroadherin demonstrated by Western blot (fig. 2).
- Electron microscopy showed filaments of intact monomeric collagen molecules with bound globules having the typical three-lobe appearance of the LRR proteins at distinct locations (Fig. 3A). To verify their nature, the complexes were incubated with gold-labeled affinity-purified antibodies to chondroadherin before electron microscopy. The picture then showed the typical IgG structure of three globes associated with the presumptive chondroadherin globules bound to collagen (fig. 3B). Thus the complexes isolated represent collagen with bound chondroadherin. No other molecules appeared to bind at these sites on collagen. Similar complexes could be formed by recombinant chondroadherin and isolated pepsinised collagen II.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00980190A EP1237568A1 (en) | 1999-11-22 | 2000-11-22 | A conjugate of a collagen ii-binding fragment and an arthritis-affecting pharmaceutical substance |
AU17486/01A AU1748601A (en) | 1999-11-22 | 2000-11-22 | A conjugate of a collagen ii-binding fragment and an arthritis-affecting pharmaceutical substance |
JP2001539475A JP2003531109A (en) | 1999-11-22 | 2000-11-22 | Conjugates of collagen II binding fragments and arthritically active pharmaceutical substances |
CA002392175A CA2392175A1 (en) | 1999-11-22 | 2000-11-22 | A conjugate of a collagen ii-binding fragment and an arthritis-affecting pharmaceutical substance |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9904237A SE9904237D0 (en) | 1999-11-22 | 1999-11-22 | New compound |
SE9904237-6 | 1999-11-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001037861A1 true WO2001037861A1 (en) | 2001-05-31 |
Family
ID=20417825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE2000/002293 WO2001037861A1 (en) | 1999-11-22 | 2000-11-22 | A conjugate of a collagen ii-binding fragment and an arthritis-affecting pharmaceutical substance |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1237568A1 (en) |
JP (1) | JP2003531109A (en) |
AU (1) | AU1748601A (en) |
CA (1) | CA2392175A1 (en) |
SE (1) | SE9904237D0 (en) |
WO (1) | WO2001037861A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003081838A (en) * | 2001-09-11 | 2003-03-19 | Rohto Pharmaceut Co Ltd | Glucosamine preparation |
WO2005105131A1 (en) * | 2004-04-30 | 2005-11-10 | Anamar Medical Ab | Modulation of cartilage homeostasis |
WO2014183214A1 (en) * | 2013-05-14 | 2014-11-20 | Haglund Lisbet | Chondroadherin fragments as indicators of intervertebral disc degeneration |
RU2584348C2 (en) * | 2011-07-28 | 2016-05-20 | Шаньшань ВАНЬ | Composite collagen sponge and method of making same |
EP2513135B1 (en) * | 2009-12-18 | 2020-04-22 | CSL Limited | Method of purifying polypeptides |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993021226A1 (en) * | 1992-04-10 | 1993-10-28 | The General Hospital Corporation | Cartilage matrix protein and methods for use |
WO1994015627A1 (en) * | 1993-01-06 | 1994-07-21 | The General Hospital Corporation | Methods for promoting cartilage matrix formation |
-
1999
- 1999-11-22 SE SE9904237A patent/SE9904237D0/en unknown
-
2000
- 2000-11-22 AU AU17486/01A patent/AU1748601A/en not_active Abandoned
- 2000-11-22 EP EP00980190A patent/EP1237568A1/en not_active Withdrawn
- 2000-11-22 JP JP2001539475A patent/JP2003531109A/en active Pending
- 2000-11-22 CA CA002392175A patent/CA2392175A1/en not_active Abandoned
- 2000-11-22 WO PCT/SE2000/002293 patent/WO2001037861A1/en not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993021226A1 (en) * | 1992-04-10 | 1993-10-28 | The General Hospital Corporation | Cartilage matrix protein and methods for use |
WO1994015627A1 (en) * | 1993-01-06 | 1994-07-21 | The General Hospital Corporation | Methods for promoting cartilage matrix formation |
Non-Patent Citations (2)
Title |
---|
CALCIFIED TISSUE INTERNATIONAL, vol. 59, no. 3, September 1996 (1996-09-01), USA, pages 163 - 167 * |
DATABASE MEDLINE [online] MIZUNO M. ET AL.: "Bone chondroadherin promotes attachment of osteoblastic cells to solid-state substrates and shows affinity", XP002951424, retrieved from 08775619 accession no. Dialog Database accession no. 96350947 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003081838A (en) * | 2001-09-11 | 2003-03-19 | Rohto Pharmaceut Co Ltd | Glucosamine preparation |
WO2005105131A1 (en) * | 2004-04-30 | 2005-11-10 | Anamar Medical Ab | Modulation of cartilage homeostasis |
US8158577B2 (en) | 2004-04-30 | 2012-04-17 | Dick Heinegard | Modulation of cartilage homeostasis by active domains of cell binding extracellular matrix molecules |
EP2513135B1 (en) * | 2009-12-18 | 2020-04-22 | CSL Limited | Method of purifying polypeptides |
EP3715356A1 (en) * | 2009-12-18 | 2020-09-30 | CSL Limited | Method of purifying polypeptides |
EP4328305A3 (en) * | 2009-12-18 | 2024-08-14 | CSL Ltd. | Method of purifying polypeptides |
RU2584348C2 (en) * | 2011-07-28 | 2016-05-20 | Шаньшань ВАНЬ | Composite collagen sponge and method of making same |
US9439999B2 (en) | 2011-07-28 | 2016-09-13 | Harbin Peiqilong Biopharmaceutical Co., Ltd | Composite collagen sponge and preparation method thereof |
WO2014183214A1 (en) * | 2013-05-14 | 2014-11-20 | Haglund Lisbet | Chondroadherin fragments as indicators of intervertebral disc degeneration |
Also Published As
Publication number | Publication date |
---|---|
AU1748601A (en) | 2001-06-04 |
SE9904237D0 (en) | 1999-11-22 |
CA2392175A1 (en) | 2001-05-31 |
JP2003531109A (en) | 2003-10-21 |
EP1237568A1 (en) | 2002-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6694409B2 (en) | TNFSF single chain molecule | |
Månsson et al. | Association of chondroadherin with collagen type II | |
Novotny et al. | Purification and properties of heparin-releasable lipoprotein-associated coagulation inhibitor | |
Becerra | Structure-function studies on PEDF: a noninhibitory serpin with neurotrophic activity | |
DiCESARE et al. | Cartilage oligomeric matrix protein and thrombospondin 1: purification from articular cartilage, electron microscopic structure, and chondrocyte binding | |
Pearse | Receptors compete for adaptors found in plasma membrane coated pits. | |
DE60028361T2 (en) | METHOD AND COMPOSITIONS FOR CARCINOMA DIAGNOSIS | |
MX2008015309A (en) | Humanized anti-human osteopontin antibody. | |
Shapiro et al. | Collagen polymorphism in extracellular matrix of human osteosarcoma | |
Moon et al. | Partial purification of neurofilament subunits from bovine brains and studies on neurofilament assembly. | |
Campistol et al. | Polymerization of normal and intact β2-microglobulin as the amyloidogenic protein in dialysis-amyloidosis | |
EP1237568A1 (en) | A conjugate of a collagen ii-binding fragment and an arthritis-affecting pharmaceutical substance | |
Foidart et al. | Laminin, a glycoprotein from basement membranes | |
Uratani et al. | Latexin, a carboxypeptidase A inhibitor, is expressed in rat peritoneal mast cells and is associated with granular structures distinct from secretory granules and lysosomes | |
JP2729712B2 (en) | Functional polypeptide | |
CN113645990A (en) | Improved prostate apoptosis response-4(PAR-4) polypeptides and methods of making and using the same | |
CN100489101C (en) | G-eGFP protein, preparation method, and application | |
AU663216B2 (en) | Bone-related cadherin-like protein and process for its production | |
KR20140028529A (en) | Linker polypeptides and metod for analyzing target material using the same | |
JPH01206998A (en) | Polypeptide having cell adhesion activity | |
Rucklidge et al. | Immunocytochemical staining of rat tissues with antibodies to denatured type I collagen: a technique for localizing areas of collagen degradation | |
JP3103531B2 (en) | Human urine-derived cell adhesion glycoprotein and method for producing the same | |
JP4121852B2 (en) | Use of an antagonist compound of protein ESM-1 for preventing and / or treating cancer, and production of a medicament for preventing and / or treating cancer | |
CN104507970B (en) | Method for preventing cancer metastasis and inhibiting inflammation by inhibiting P68 interaction with calmodulin | |
AU784614B2 (en) | Immune modulation with death receptor-induced apoptosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 17486/01 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2392175 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 539475 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000980190 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000980190 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000980190 Country of ref document: EP |